World-Renowned Alzheimer's Expert Prof. Steven Arnold Joins NeuroSense SAB [Yahoo! Finance]
NeuroSense Therapeutics Ltd. (NRSN)
Company Research
Source: Yahoo! Finance
Jan. 8, 2026 /PRNewswire/ -- NeuroSense Therapeutics Ltd. (NASDAQ: NRSN) ("NeuroSense"), a late-clinical stage biotechnology company developing novel treatments for severe neurodegenerative diseases, today announced that Prof. Steven E. Arnold, a world-renowned Alzheimer's disease expert and Professor of Neurology at Harvard Medical School, has joined the Company's Scientific Advisory Board. Prof. Arnold brings decades of experience in neurodegenerative disease research, biomarker-driven clinical development, and translational neuroscience, further strengthening NeuroSense's scientific leadership as it advances PrimeC in ALS and expands its Alzheimer's disease program. "Prof. Arnold's depth of experience in biomarker-driven clinical development and translational neuroscience aligns closely with how we are advancing our programs," said Alon Ben-Noon, Co-Founder and Chief Executive Officer of NeuroSense. "His perspective will be valuable as we continue to execute across both Alzheimer
Show less
Read more
Impact Snapshot
Event Time:
NRSN
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
NRSN alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
NRSN alerts
High impacting NeuroSense Therapeutics Ltd. news events
Weekly update
A roundup of the hottest topics
NRSN
News
- World-Renowned Alzheimer's Expert Prof. Steven Arnold Joins NeuroSense SABPR Newswire
- NeuroSense Therapeutics (NASDAQ:NRSN) was upgraded by analysts at <a style="font-weight:bold" href="https://www.wallstreetzen.com/newsletters/zen-ratings?ticker=NRSN&utm_campaign=getratings&utm_medium=online&utm_source=MarketBeat">Wall SMarketBeat
- NeuroSense Therapeutics (NASDAQ:NRSN) had its "buy" rating reaffirmed by analysts at D. Boral Capital. They now have a $14.00 price target on the stock.MarketBeat
- NeuroSense Confirms Favorable Safety and Tolerability of PrimeC in an Alzheimer's Phase 2 Study [Yahoo! Finance]Yahoo! Finance
- NeuroSense Confirms Favorable Safety and Tolerability of PrimeC in an Alzheimer's Phase 2 StudyPR Newswire
NRSN
Sec Filings
- 1/6/26 - Form 6-K
- 12/22/25 - Form 6-K
- 12/8/25 - Form 6-K
- NRSN's page on the SEC website